If AMST PR regarding Histostem 2009 financials is accurate, and if the company gets on track 1st calendar quarter next year with a couple of their major initiatives, and if financials are filed, then what will our valuation be?? Here is a guess. I know I'm entertaining a lot of positives above, but you gotta remember I'm the one that actually thinks Dwight/Hawk/Han are moving things forward. Anyway, my comparison is against ISCO since they seem to be in the same type of business (at least with commericialization of their stem cell facial cream). ISCO has 72M shares o/s and is on track for about 1.5M in revs with a net loss somewhere north of 3M (see their financials on pinksheets to verify). They are currently trading around 1.90ish. AMST has 180M shares o/s with Histostem apparently earning 5.4M in revs for 2009 with 1.4M net profit (per 4/5/2010 PR). They are earning more money than ISCO (not verified yet due to no financials -- once again assuming the PR AMST issued is accurate). Using even the simplest comparison that AMST has 2.5X more o/s than ISCO, a straight up PPS comparison would place AMST in the .75 cent range (market cap of 135M). Keep in mind that AMST valuation in based solely on Histostem earnings in Asia. Imagine what happens if and when they actually break into the N. American market (hopefully coming soon to a theatre near you (LOL)). Anyway, this is about as cavemanish a comparison as I can come up with. But, it should get the point across about where we may end up in the short term (6 Months). All this being said we are currently a non-reporting pink sheet very high risk very high reward stock. Anyway, just something to chew on while we wait for a news item from the company.
AI
Market Data 
Markets 
